Summary & Overview
HCPCS Q4168: Amnioband, 1 mg
HCPCS Level II code Q4168 designates a 1 mg unit of Amnioband, an amniotic-tissue–derived biologic used as an adjunct in wound healing and tissue repair. This product-level code matters nationally because it identifies a specific biologic supply used across outpatient procedures and wound-care services, influencing coding accuracy, product tracking, and payer coverage determinations.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for Amnioband, the common sites of service where the product is used, and the payers typically relevant for coverage considerations. The publication also presents benchmarks and policy-focused content relevant to providers, billing staff, and revenue-cycle professionals, including common modifiers and coding relationships where available.
The report provides practical reference material on how this HCPCS Level II code fits into outpatient biologic and wound-care workflows, highlights areas where payers may apply medical policy or billing guidelines, and summarizes the information needed for accurate claim submission. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4168 describes Amnioband, 1 mg, a biologic product derived from amniotic tissue intended for clinical use in wound healing or tissue repair. The service type for this code is a biologic implant or topical biologic therapy. The typical site of service is outpatient surgical suites, ambulatory surgery centers, and hospital outpatient departments where biologic wound-care adjuncts or graft-materials are applied.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pregnant patient in the second trimester (commonly between 16–24 weeks gestation) presents for membrane support using an amniotic membrane-derived product. The clinical workflow begins with an obstetric or maternal-fetal medicine evaluation for indications such as amniotic band syndrome risk, membrane defects, or to support fetal structural repair during minimally invasive fetal surgery. After counseling and informed consent, the patient is taken to an ambulatory surgery center or hospital outpatient department. Under ultrasound guidance and local or regional anesthesia with possible conscious sedation, the provider administers the amnioband product (Q4168, Amnioband, 1 mg) into the target area via a small-caliber introducer or injection device. Post-procedure monitoring includes fetal heart rate assessment, ultrasound confirmation of placement, and brief outpatient observation before discharge with follow-up prenatal surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No Modifier / Unspecified | Use when no specific modifier applies and payer requires a two-character notation for no additional modifier. |
22 |